• Like
3 Humongous Healthcare Stocks This Week   2-21-14
Upcoming SlideShare
Loading in...5

Thanks for flagging this SlideShare!

Oops! An error has occurred.

3 Humongous Healthcare Stocks This Week 2-21-14


3 of the biggest healthcare winners of the week

3 of the biggest healthcare winners of the week

Published in Health & Medicine
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
No Downloads


Total Views
On SlideShare
From Embeds
Number of Embeds



Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

    No notes for slide
  • http://www.fool.com/investing/general/2014/02/04/why-furiex-pharmaceuticals-inc-shares-furiously-do.aspx
  • http://finance.yahoo.com/news/ohr-pharmaceutical-present-16th-annual-131500941.html
  • http://finance.yahoo.com/news/athenahealth-surges-stronger-expected-4q-181446268.html
  • http://investor.furiex.com/releasedetail.cfm?ReleaseID=822849


  • 1. 3 Humongous Health-Care Stocks This Week
  • 2. The Winter Olympics in Sochi, Russia, wasn’t the only place to find big winners this week. Several health-care stocks also deserved gold medals for fantastic performances. Source: Wikimedia Commons.
  • 3. Forest Laboratories (NYSE: FRX) Shares of this drugmaker soared nearly 36% this week.
  • 4. Why did Forest catch on fire? • Specialty pharmaceutical firm Actavis (NYSE: ACT) announced a $25 billion buyout of Forest Labs. • The deal will result in combined revenues of $15 billion. • Expected operating synergies are around $1 billion.
  • 5. China Biologic Products (Nasdaq: CBPO) Shares of the biopharmaceutical company surged almost 33% higher for the week.
  • 6. Why did China Biologic jump a great wall? • No big new announcements from the company this week. • The earnings announcement is still a few weeks away. • The company has bought back shares in recent months.
  • 7. Chelsea Therapeutics (Nasdaq: CHTP) Shares of the biotech climbed nearly 28% this week.
  • 8. Why did Chelsea shares head north? • Northera gained approval from the FDA. • The drug treats neurogenic orthostatic hypotension (NOH), a disorder that affects 80,000 to 150,000 Americans. • Chelsea expects to launch Northera in the second half of 2014.
  • 9. Best pick to stay humongous? • The FDA win for Northera puts Chelsea in a great position. • Additional studies are required since Northera received accelerated approval, but results will likely be positive. • Chelsea appears poised to attract interest from larger partners.
  • 10. Find out which stock The Motley Fool’s chief investment officer selected as the top pick for 2014 in our free report!